{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-04T18:12:51.653251+00:00","company":{"ticker":"ANGO","cik":1275187,"company_name":"ANGIODYNAMICS INC"},"pagination":{"limit":100,"returned":3,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","facts":[{"fact_type":"earnings_release","fact_key":"acc9aa6442e0e686fd5bc05ab04d6b9e7f0a229d","cik":1275187,"ticker":"ANGO","company_name":"ANGIODYNAMICS INC","filed_at":"2026-04-02T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"raised","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"third quarter of fiscal year 2026 ended February 28, 2026","report_date":"2026-04-02","result_type":"reported_results","revenue_text":"$78.4 million"},"claim":"ANGIODYNAMICS INC reported third quarter of fiscal year 2026 ended February 28, 2026 results: revenue $78.4 million. Guidance raised.","evidence_excerpt":"the third quarter of fiscal year 2026, which ended February 28, 2026. Fiscal Year 2026 Third Quarter Highlights Quarter Ended February 28, 2026 Pro Forma* YoY Growth Net Sales $78.4 million 8.9% Med Tech Net Sales $37.3 million 19.0% Med Device Net Sales $41.1 million 1.1% • GAAP gross margin of 52.9% • GAAP loss per share of $0.19 • Adjusted loss per share of $0.07","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001140361-26-012891","anchor_url":"https://secwatch.observer/filing/0001140361-26-012891#claim-acc9aa6442e0e686fd5bc05ab04d6b9e7f0a229d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1275187/000114036126012891/0001140361-26-012891-index.htm"},{"fact_type":"earnings_release","fact_key":"624bda47c545940febd6de6e0031a9c9ec2b6b4f","cik":1275187,"ticker":"ANGO","company_name":"ANGIODYNAMICS INC","filed_at":"2024-04-04T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the fiscal third quarter ended February 29, 2024","report_date":"2024-04-04","result_type":"reported_results","revenue_text":null},"claim":"ANGIODYNAMICS INC reported financial results for the fiscal third quarter ended February 29, 2024.","evidence_excerpt":"On April 4, 2024, AngioDynamics issued a press release announcing financial results for the fiscal third quarter ended February 29, 2024.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001140361-24-017807","anchor_url":"https://secwatch.observer/filing/0001140361-24-017807#claim-624bda47c545940febd6de6e0031a9c9ec2b6b4f","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1275187/000114036124017807/0001140361-24-017807-index.htm"},{"fact_type":"material_agreement","fact_key":"9a2ecb026f6e8054897932abb7f52c00f428d065","cik":1275187,"ticker":"ANGO","company_name":"ANGIODYNAMICS INC","filed_at":"2024-04-01T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Settlement Agreement","agreement_type":"settlement","counterparty":"Becton, Dickinson and Company, C.R. Bard, Inc. and Bard Peripheral Vascular Inc.","effective_date":"2024-03-31","item_codes_triggered":["1.01"],"value_text":"one-time lump sum payment to BD in the amount of $7 million, $3 million of which will be payable wit"},"claim":"ANGIODYNAMICS INC entered into Settlement Agreement with Becton, Dickinson and Company, C.R. Bard, Inc. and Bard Peripheral Vascular Inc. valued at one-time lump sum payment to BD in the amount of $7 million, $3 million of which will be payable wit (effective 2024-03-31).","evidence_excerpt":"On March 31, 2024, AngioDynamics and BD entered into a Settlement Agreement (the “Settlement Agreement”) to resolve the Actions.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001140361-24-016977","anchor_url":"https://secwatch.observer/filing/0001140361-24-016977#claim-9a2ecb026f6e8054897932abb7f52c00f428d065","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1275187/000114036124016977/0001140361-24-016977-index.htm"}]}